FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220789966> ?p ?o ?g. }

• W4220789966 endingPage "2656" @default.
• W4220789966 startingPage "2646" @default.
• W4220789966 abstract "Abstract Purpose: Kaposi sarcoma (KS), an endothelial cell tumor associated with KS herpesvirus (KSHV), remains among the most common malignancies occurring with HIV infection (HIV-KS). As an oral anti-inflammatory, antiangiogenic, and immunomodulatory agent, lenalidomide is potentially an attractive alternative to standard chemotherapy for KS. Experimental Design: The primary objectives of this phase I/II trial were to determine the maximum tolerated dose (MTD) and response rates for lenalidomide in HIV-KS. Secondary objectives included correlating response with natural killer (NK) and T-cell subsets, plasma cytokines, viral copy number, and KSHV gene expression in biopsies. Four dose levels of oral lenalidomide taken 21 consecutive days of 28-day cycles were evaluated in adults with HIV-KS on antiretroviral therapy with controlled viremia. Results: Fifteen and 23 participants enrolled in phases I and II, respectively, 76% of whom had received prior KS therapy. The MTD was not reached, declaring 25 mg as the recommended phase II dose (RP2D). The most frequent adverse events were neutropenia, fatigue, leukopenia, and diarrhea. Of the 25 evaluable participants receiving RP2D, 60% responded. Correlative studies performed in a subset of participants demonstrated a significant increase in proportions of blood T cells with T-regulatory phenotype, and plasma cytokines trended toward a less inflammatory pattern. Clinical response was associated with loss of KSHV transcription. Conclusions: Lenalidomide is active in HIV-KS. The most common adverse events were manageable. With 60% of participants receiving RP2D obtaining a partial response and &lt;10% discontinuing due to adverse events, the response and tolerability to lenalidomide support its use in HIV-KS. See related commentary by Henry and Maki, p. 2485" @default.
• W4220789966 created "2022-04-03" @default.
• W4220789966 creator A5012846289 @default.
• W4220789966 creator A5028224724 @default.
• W4220789966 creator A5032508652 @default.
• W4220789966 creator A5041987464 @default.
• W4220789966 creator A5043433202 @default.
• W4220789966 creator A5051407280 @default.
• W4220789966 creator A5053034775 @default.
• W4220789966 creator A5059154513 @default.
• W4220789966 creator A5063693935 @default.
• W4220789966 creator A5068593672 @default.
• W4220789966 creator A5078930934 @default.
• W4220789966 creator A5079751653 @default.
• W4220789966 creator A5087813701 @default.
• W4220789966 creator A5090553690 @default.
• W4220789966 date "2022-03-01" @default.
• W4220789966 modified "2023-10-10" @default.
• W4220789966 title "AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma" @default.
• W4220789966 cites W158204501 @default.
• W4220789966 cites W1946820747 @default.
• W4220789966 cites W1962046702 @default.
• W4220789966 cites W1973249762 @default.
• W4220789966 cites W1976824810 @default.
• W4220789966 cites W1982097210 @default.
• W4220789966 cites W1993122793 @default.
• W4220789966 cites W1998665041 @default.
• W4220789966 cites W2002557186 @default.
• W4220789966 cites W2014571799 @default.
• W4220789966 cites W2023914649 @default.
• W4220789966 cites W2024483482 @default.
• W4220789966 cites W2046525111 @default.
• W4220789966 cites W2049400800 @default.
• W4220789966 cites W2056291926 @default.
• W4220789966 cites W2066250170 @default.
• W4220789966 cites W2069619905 @default.
• W4220789966 cites W2075235017 @default.
• W4220789966 cites W2084579140 @default.
• W4220789966 cites W2097681908 @default.
• W4220789966 cites W2105109537 @default.
• W4220789966 cites W2106286457 @default.
• W4220789966 cites W2116496248 @default.
• W4220789966 cites W2128640763 @default.
• W4220789966 cites W2133082612 @default.
• W4220789966 cites W2150461868 @default.
• W4220789966 cites W2411668137 @default.
• W4220789966 cites W2511002777 @default.
• W4220789966 cites W2518488421 @default.
• W4220789966 cites W2519978149 @default.
• W4220789966 cites W2528836681 @default.
• W4220789966 cites W2561926137 @default.
• W4220789966 cites W2809536934 @default.
• W4220789966 cites W2890620186 @default.
• W4220789966 cites W2911941951 @default.
• W4220789966 cites W4313376856 @default.
• W4220789966 doi "https://doi.org/10.1158/1078-0432.ccr-21-0645" @default.
• W4220789966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35247913" @default.
• W4220789966 hasPublicationYear "2022" @default.
• W4220789966 type Work @default.
• W4220789966 citedByCount "5" @default.
• W4220789966 countsByYear W42207899662023 @default.
• W4220789966 crossrefType "journal-article" @default.
• W4220789966 hasAuthorship W4220789966A5012846289 @default.
• W4220789966 hasAuthorship W4220789966A5028224724 @default.
• W4220789966 hasAuthorship W4220789966A5032508652 @default.
• W4220789966 hasAuthorship W4220789966A5041987464 @default.
• W4220789966 hasAuthorship W4220789966A5043433202 @default.
• W4220789966 hasAuthorship W4220789966A5051407280 @default.
• W4220789966 hasAuthorship W4220789966A5053034775 @default.
• W4220789966 hasAuthorship W4220789966A5059154513 @default.
• W4220789966 hasAuthorship W4220789966A5063693935 @default.
• W4220789966 hasAuthorship W4220789966A5068593672 @default.
• W4220789966 hasAuthorship W4220789966A5078930934 @default.
• W4220789966 hasAuthorship W4220789966A5079751653 @default.
• W4220789966 hasAuthorship W4220789966A5087813701 @default.
• W4220789966 hasAuthorship W4220789966A5090553690 @default.
• W4220789966 hasBestOaLocation W42207899662 @default.
• W4220789966 hasConcept C126322002 @default.
• W4220789966 hasConcept C142724271 @default.
• W4220789966 hasConcept C143998085 @default.
• W4220789966 hasConcept C197934379 @default.
• W4220789966 hasConcept C203014093 @default.
• W4220789966 hasConcept C2776063141 @default.
• W4220789966 hasConcept C2776364478 @default.
• W4220789966 hasConcept C2776694085 @default.
• W4220789966 hasConcept C2777063308 @default.
• W4220789966 hasConcept C2778256501 @default.
• W4220789966 hasConcept C2778375690 @default.
• W4220789966 hasConcept C2780873365 @default.
• W4220789966 hasConcept C71924100 @default.
• W4220789966 hasConcept C90924648 @default.
• W4220789966 hasConceptScore W4220789966C126322002 @default.
• W4220789966 hasConceptScore W4220789966C142724271 @default.
• W4220789966 hasConceptScore W4220789966C143998085 @default.
• W4220789966 hasConceptScore W4220789966C197934379 @default.
• W4220789966 hasConceptScore W4220789966C203014093 @default.
• W4220789966 hasConceptScore W4220789966C2776063141 @default.
• W4220789966 hasConceptScore W4220789966C2776364478 @default.

• next